CY1124074T1 - Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων - Google Patents
Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδωνInfo
- Publication number
- CY1124074T1 CY1124074T1 CY20211100191T CY211100191T CY1124074T1 CY 1124074 T1 CY1124074 T1 CY 1124074T1 CY 20211100191 T CY20211100191 T CY 20211100191T CY 211100191 T CY211100191 T CY 211100191T CY 1124074 T1 CY1124074 T1 CY 1124074T1
- Authority
- CY
- Cyprus
- Prior art keywords
- glucocorticoids
- relates
- glucocorticoid
- component
- designed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
Η εφεύρεση σχετίζεται με θεραπεία υποκατάστασης γλυκοκορτικοειδών και παρέχει φαρμακευτικές συνθέσεις και κιτ σχεδιασμένα για την παροχή ενός ή περισσοτέρων γλυκοκορτικοειδών σε έναν ασθενή με ανάγκη αυτών με έναν τρόπο που έχει ως αποτέλεσμα επίπεδα ορού του γλυκοκορτικοειδούς που ουσιαστικά μιμούνται εκείνο ενός υγιούς ατόμου για μία κλινικώς ενδεδειγμένη χρονική περίοδο. Η φαρμακευτική σύνθεση περιλαμβάνει ένα ή περισσότερα γλυκοκορτικοειδή, όπου ένα πρώτο τμήμα ενός ή περισσοτέρων γλυκοκορτικοειδών απελευθερώνεται ουσιαστικά άμεσα και ένα δεύτερο τμήμα ενός ή περισσοτέρων γλυκοκορτικοειδών απελευθερώνεται επί ένα παρατεταμένο χρονικό διάστημα τουλάχιστον περίπου 8 ωρών, και η ποσότητα του ενός ή περισσοτέρων γλυκοκορτικοειδών του πρώτου τμήματος, εκφραζόμενα ως ισοδύναμα υδροκορτιζόνης, είναι σε ένα διάστημα από περίπου 15 έως περίπου 50% των συνολικών ισοδυνάμων υδροκορτιζόνης. Η εφεύρεση επίσης σχετίζεται με ένα κιτ που περιλαμβάνει ένα πρώτο και ένα δεύτερο συστατικό, όπου το πρώτο συστατικό είναι σχεδιασμένο για να απελευθερώνει ένα ή περισσότερα γλυκοκορτικοειδή ουσιαστικά άμεσα και το δεύτερο συστατικό είναι σχεδιασμένο για να απελευθερώνει ένα ή περισσότερα γλυκοκορτικοειδή επί ένα παρατεταμένο χρονικό διάστημα τουλάχιστον 8 ωρών. Η εφεύρεση επίσης σχετίζεται με μία μέθοδο αγωγής νόσων που απαιτούν αγωγή με γλυκοκορτικοειδή όπως σε ασθενείς που έχουν μία διαταραχή ανεπάρκειας γλυκοκορτικοειδών. Σε μία άλλη άποψη, η εφεύρεση σχετίζεται με τη χρήση μίας πρώτης και μίας δεύτερης ποσότητας ενός ή περισσοτέρων γλυκοκορτικοειδών για την παρασκευή μίας φαρμακευτικής σύνθεσης ή κιτ για την αγωγή μίας διαταραχής ανεπάρκειας γλυκοκορτικοειδών.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56420504P | 2004-04-22 | 2004-04-22 | |
SE0401031A SE0401031D0 (sv) | 2004-04-22 | 2004-04-22 | A new glucocorticoid replacement therapy |
EP05735076.1A EP1744730B1 (en) | 2004-04-22 | 2005-04-21 | Pharmaceutical compositions for glucocorticoid replacement therapy |
PCT/EP2005/004400 WO2005102271A2 (en) | 2004-04-22 | 2005-04-21 | Pharmaceutical compositions for glucocorticoid replacement therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124074T1 true CY1124074T1 (el) | 2022-03-24 |
Family
ID=35197481
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161101091T CY1118275T1 (el) | 2004-04-22 | 2016-10-26 | Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων |
CY20211100191T CY1124074T1 (el) | 2004-04-22 | 2021-03-05 | Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161101091T CY1118275T1 (el) | 2004-04-22 | 2016-10-26 | Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων |
Country Status (26)
Country | Link |
---|---|
US (3) | US8425937B2 (el) |
EP (2) | EP1744730B1 (el) |
JP (2) | JP5149618B2 (el) |
CN (2) | CN1942176B (el) |
AU (1) | AU2005235370B2 (el) |
BR (1) | BRPI0510044B8 (el) |
CA (1) | CA2564000C (el) |
CY (2) | CY1118275T1 (el) |
DK (2) | DK3072507T3 (el) |
ES (2) | ES2600556T3 (el) |
HK (1) | HK1179525A1 (el) |
HR (2) | HRP20161380T1 (el) |
HU (2) | HUE053248T2 (el) |
IL (2) | IL178776A (el) |
LT (2) | LT3072507T (el) |
ME (1) | ME02584B (el) |
MX (2) | MX344197B (el) |
NZ (1) | NZ585340A (el) |
PL (2) | PL3072507T3 (el) |
PT (2) | PT1744730T (el) |
RS (2) | RS61501B1 (el) |
SE (1) | SE0401031D0 (el) |
SG (1) | SG188081A1 (el) |
SI (1) | SI3072507T1 (el) |
WO (1) | WO2005102271A2 (el) |
ZA (1) | ZA200609680B (el) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0401031D0 (sv) * | 2004-04-22 | 2004-04-22 | Duocort Ab | A new glucocorticoid replacement therapy |
US9925139B2 (en) | 2004-04-22 | 2018-03-27 | Acucort Ab | Pharmaceutical compositions for acute glucocorticoid therapy |
JP2009518405A (ja) * | 2005-12-06 | 2009-05-07 | モノソル アールエックス リミテッド ライアビリティ カンパニー | 活性物質の送達のための局所フィルム組成物 |
FR2926722B1 (fr) * | 2008-01-25 | 2010-09-03 | Substipharm Dev | Formulation pharmaceutique appropriee pour la preparation de comprimes orodispersibles de prednisolone |
PT2151235E (pt) * | 2008-07-21 | 2011-03-21 | Falk Pharma Gmbh | Formulação farmacêutica para o tratamento do trato digestivo superior |
BRPI1011624A2 (pt) | 2009-04-07 | 2016-03-22 | Duocort Pharma Ab | composição, métodos para reduzir um ou mais efeitos colaterais da terapia de glicocorticóide, e para tratar ou previnir um padrão de secreção de glicocorticóide endógeno diminuído ou interrompido em um paciente. |
CN102933218A (zh) | 2010-05-20 | 2013-02-13 | 杜奥科特药物公司 | 糖皮质激素基的组合物的剂量学和施用 |
GB201119985D0 (en) * | 2011-11-19 | 2012-01-04 | Diurnal Ltd | Treatment of adrenal insufficiency |
GB201202433D0 (en) | 2012-02-13 | 2012-03-28 | Diurnal Ltd | Controlled drug release |
JP2014086673A (ja) | 2012-10-26 | 2014-05-12 | Mitsubishi Electric Corp | モノリシック集積回路 |
DK2914255T3 (da) | 2012-11-02 | 2021-10-25 | Murray & Poole Entpr Ltd | Behandling eller forebyggelse af kardiovaskulære hændelser via administration af colchicin |
AU2014255434B2 (en) | 2013-04-16 | 2018-11-08 | Murray And Poole Enterprises Limited | Sustained-release formulations of colchicine and methods of using same |
GB201308933D0 (en) | 2013-05-17 | 2013-07-03 | Diurnal Ltd | Paediatric composition |
MX348595B (es) * | 2013-08-02 | 2017-06-21 | Laboratorio Raam De Sahuayo S A De C V | Composicion farmaceutica con agentes antiinflamatorios y proceso de produccion. |
PT2886108T (pt) | 2013-12-23 | 2019-04-01 | Dr Falk Pharma Gmbh | Formulação farmacêutica otimizada para o tratamento de alterações inflamatórias do esófago |
SG11201707525TA (en) | 2015-03-30 | 2017-10-30 | Corcept Therapeutics Inc | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency |
CN107115308B (zh) * | 2016-02-23 | 2021-02-23 | 天津金耀集团有限公司 | 一种氢化可的松双相缓释片剂组合物 |
RU2748437C2 (ru) * | 2019-10-28 | 2021-05-25 | Федеральное государственное бюджетное учреждение науки Институт цитологии Российской академии наук (ИНЦ РАН) | Производное гидрокортизона в качестве средства для лечения болезни Альцгеймера |
FR3116439B1 (fr) * | 2020-11-26 | 2023-08-04 | Laboratoire Dielen | Comprimé pelliculé contenant au moins un principe actif, adapté à l’administration par voie orale dudit au moins un principe actif chez des sujets humains |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2260384C3 (de) * | 1972-12-09 | 1979-11-29 | Hoechst Ag, 6000 Frankfurt | Oral zu applizierendes Corticosteroid-Präparat |
US5316772A (en) * | 1990-12-19 | 1994-05-31 | Solvay & Cie, S.A. (Societe Anonyme) | Bilayered oral pharmaceutical composition with pH dependent release |
US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5314697A (en) | 1992-10-23 | 1994-05-24 | Schering Corporation | Stable extended release oral dosage composition comprising loratadine and pseudoephedrine |
TW391880B (en) | 1994-01-31 | 2000-06-01 | Yamanouchi Pharma Co Ltd | An oral soluble type compression moulding and its preparation |
US5534263A (en) | 1995-02-24 | 1996-07-09 | Alza Corporation | Active agent dosage form comprising a matrix and at least two insoluble bands |
US5976573A (en) | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
DE19718012C1 (de) * | 1997-04-29 | 1998-10-08 | Jenapharm Gmbh | Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe |
US6602521B1 (en) * | 1998-09-29 | 2003-08-05 | Impax Pharmaceuticals, Inc. | Multiplex drug delivery system suitable for oral administration |
US6500459B1 (en) * | 1999-07-21 | 2002-12-31 | Harinderpal Chhabra | Controlled onset and sustained release dosage forms and the preparation thereof |
US6156743A (en) * | 1999-10-18 | 2000-12-05 | Whitcomb; John E. | Method of decreasing fatigue |
AR026148A1 (es) * | 2000-01-21 | 2003-01-29 | Osmotica Argentina S A | Dispositivo osmotico con pasaje preformado que aumenta de tamano |
HUP0501071A3 (en) | 2001-03-13 | 2007-06-28 | Penwest Pharmaceutical Co | Chronotherapeutic dosage forms |
ATE477804T1 (de) * | 2001-03-15 | 2010-09-15 | Soligenix Inc | Verfahren zur behandlung von entzündlichen erkrankungen des verdauungstrakts mit topisch wirksamen kortikosteroiden |
GB0119848D0 (en) | 2001-08-15 | 2001-10-10 | Univ Sheffield | Delayed and sustained drug release |
US6682759B2 (en) * | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
CN100346832C (zh) * | 2002-02-07 | 2007-11-07 | 法玛西雅公司 | 经粘膜递送的药物剂型 |
GB0400031D0 (en) | 2004-01-03 | 2004-02-04 | Univ Sheffield | Depression treatment |
US9925139B2 (en) | 2004-04-22 | 2018-03-27 | Acucort Ab | Pharmaceutical compositions for acute glucocorticoid therapy |
SE0401031D0 (sv) * | 2004-04-22 | 2004-04-22 | Duocort Ab | A new glucocorticoid replacement therapy |
GB0623740D0 (en) | 2006-11-28 | 2007-01-10 | Diurnal Ltd | Treatment of disease |
BRPI1011624A2 (pt) | 2009-04-07 | 2016-03-22 | Duocort Pharma Ab | composição, métodos para reduzir um ou mais efeitos colaterais da terapia de glicocorticóide, e para tratar ou previnir um padrão de secreção de glicocorticóide endógeno diminuído ou interrompido em um paciente. |
CN102933218A (zh) | 2010-05-20 | 2013-02-13 | 杜奥科特药物公司 | 糖皮质激素基的组合物的剂量学和施用 |
-
2004
- 2004-04-22 SE SE0401031A patent/SE0401031D0/xx unknown
-
2005
- 2005-04-21 RS RS20210233A patent/RS61501B1/sr unknown
- 2005-04-21 JP JP2007508863A patent/JP5149618B2/ja active Active
- 2005-04-21 HU HUE16169413A patent/HUE053248T2/hu unknown
- 2005-04-21 MX MX2013004889A patent/MX344197B/es unknown
- 2005-04-21 PT PT57350761T patent/PT1744730T/pt unknown
- 2005-04-21 CA CA2564000A patent/CA2564000C/en active Active
- 2005-04-21 EP EP05735076.1A patent/EP1744730B1/en active Active
- 2005-04-21 SI SI200532291T patent/SI3072507T1/sl unknown
- 2005-04-21 DK DK16169413.8T patent/DK3072507T3/da active
- 2005-04-21 WO PCT/EP2005/004400 patent/WO2005102271A2/en active Application Filing
- 2005-04-21 PL PL16169413T patent/PL3072507T3/pl unknown
- 2005-04-21 AU AU2005235370A patent/AU2005235370B2/en active Active
- 2005-04-21 ME MEP-2016-250A patent/ME02584B/me unknown
- 2005-04-21 BR BRPI0510044A patent/BRPI0510044B8/pt active IP Right Grant
- 2005-04-21 DK DK05735076.1T patent/DK1744730T3/en active
- 2005-04-21 US US11/587,514 patent/US8425937B2/en active Active
- 2005-04-21 EP EP16169413.8A patent/EP3072507B1/en active Active
- 2005-04-21 CN CN2005800118623A patent/CN1942176B/zh active Active
- 2005-04-21 ES ES05735076.1T patent/ES2600556T3/es active Active
- 2005-04-21 MX MXPA06012011A patent/MXPA06012011A/es active IP Right Grant
- 2005-04-21 HU HUE05735076A patent/HUE030546T2/en unknown
- 2005-04-21 CN CN201210499801.8A patent/CN103006592B/zh active Active
- 2005-04-21 PT PT161694138T patent/PT3072507T/pt unknown
- 2005-04-21 SG SG2013005244A patent/SG188081A1/en unknown
- 2005-04-21 RS RS20160749A patent/RS55198B1/sr unknown
- 2005-04-21 PL PL05735076T patent/PL1744730T3/pl unknown
- 2005-04-21 NZ NZ585340A patent/NZ585340A/en active IP Right Revival
- 2005-04-21 LT LTEP16169413.8T patent/LT3072507T/lt unknown
- 2005-04-21 ES ES16169413T patent/ES2857600T3/es active Active
- 2005-04-21 LT LTEP05735076.1T patent/LT1744730T/lt unknown
-
2006
- 2006-10-19 IL IL178776A patent/IL178776A/en active IP Right Grant
- 2006-11-21 ZA ZA200609680A patent/ZA200609680B/xx unknown
-
2012
- 2012-08-03 JP JP2012173158A patent/JP5681679B2/ja active Active
- 2012-12-20 US US13/722,013 patent/US20130129823A1/en not_active Abandoned
-
2013
- 2013-06-07 HK HK13106780.6A patent/HK1179525A1/zh unknown
- 2013-07-08 IL IL227375A patent/IL227375A/en active IP Right Grant
-
2014
- 2014-04-17 US US14/255,332 patent/US10583146B2/en active Active
-
2016
- 2016-10-24 HR HRP20161380TT patent/HRP20161380T1/hr unknown
- 2016-10-26 CY CY20161101091T patent/CY1118275T1/el unknown
-
2021
- 2021-03-01 HR HRP20210348TT patent/HRP20210348T1/hr unknown
- 2021-03-05 CY CY20211100191T patent/CY1124074T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124074T1 (el) | Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων | |
ATE529125T1 (de) | Pharmazeutische zusammensetzungen und verfahren zur beschleunigung der wundheilung | |
MA28935B1 (fr) | Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite | |
ATE450251T1 (de) | Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung | |
DE602004031134D1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
BR0211062A (pt) | Combinações para o tratamento de distúrbios inflamatórios | |
BRPI0519195A2 (pt) | composiÇço de cuidado oral, e, mÉtodo para prevenir ou tratar cÁrie dental em um indivÍduo humano ou animal | |
EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
EA200501319A1 (ru) | Способы лечения боли введением антагониста фактора роста нервов и нестероидного противовоспалительного средства и содержащие их композиции | |
DE60302348D1 (de) | Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen | |
EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
EA200900203A1 (ru) | Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение | |
BR0318269A (pt) | composições, alvos, métodos e dispositivos para a terapia de distúrbios oculares e perioculares | |
ATE544460T1 (de) | Zusammensetzungen und verfahren für eine gesunde schwangerschaft | |
EA200870254A1 (ru) | Способ лечения воспалительных заболеваний | |
BRPI0411319A (pt) | compostos terapeuticamente ativos e sua utilização | |
BR0206639A (pt) | Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares | |
de Campos et al. | Smoking modulates gene expression of type I collagen, bone sialoprotein, and osteocalcin in human alveolar bone | |
ATE541567T1 (de) | Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat- derivaten | |
BRPI0413404A (pt) | composições farmacêuticas, métodos de tratamento ou prevenção de disfunções cardìacas, métodos de aumento da função cardìaca e método de identificação de inibidor de mif | |
BR0308584A (pt) | Composição farmacêutica androgênica e método para tratamento de depressão | |
BR0312929A (pt) | Uso de um composto, e, métodos de tratamento, prevenção ou alìvio de uma doença, distúrbio ou condição de um corpo de animal vivo, e da degeneração macular relacionada com a idade de um corpo de animal vivo | |
ATE406158T1 (de) | Verwendung von vitamin c zur behandlung der charcot-marie-tooth krankheit | |
Rokohl et al. | Socket discomfort in anophthalmic patients—reasons and therapy options | |
DE602004025936D1 (de) | Therapeutische zusammensetzung enthaltend dentritische zellen und ihre verwendung |